176 related articles for article (PubMed ID: 27336583)
1. Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Ma Z; Lynch AS
J Med Chem; 2016 Jul; 59(14):6645-57. PubMed ID: 27336583
[TBL] [Abstract][Full Text] [Related]
2. Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
Li J; Ma Z; Chapo K; Yan D; Lynch AS; Ding CZ
Bioorg Med Chem Lett; 2007 Oct; 17(20):5510-3. PubMed ID: 17826091
[TBL] [Abstract][Full Text] [Related]
3. Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA.
Sanchez CJ; Shiels SM; Tennent DJ; Hardy SK; Murray CK; Wenke JC
Clin Orthop Relat Res; 2015 Sep; 473(9):2874-84. PubMed ID: 25896136
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Robertson GT; Bonventre EJ; Doyle TB; Du Q; Duncan L; Morris TW; Roche ED; Yan D; Lynch AS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2313-23. PubMed ID: 18443108
[TBL] [Abstract][Full Text] [Related]
5. The antibacterial activity of a new 3-azinomethyl-rifamycin.
Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
[TBL] [Abstract][Full Text] [Related]
6. The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
Przybylski P; Pyta K; Czerwonka D; Kubicka MM; Gajecka M
Bioorg Med Chem Lett; 2015 Sep; 25(18):3903-9. PubMed ID: 26254943
[TBL] [Abstract][Full Text] [Related]
7. Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.
Lan T; Ganapathy US; Sharma S; Ahn YM; Zimmerman M; Molodtsov V; Hegde P; Gengenbacher M; Ebright RH; Dartois V; Freundlich JS; Dick T; Aldrich CC
Angew Chem Int Ed Engl; 2022 Nov; 61(45):e202211498. PubMed ID: 36222275
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
[TBL] [Abstract][Full Text] [Related]
10. Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against Staphylococcus aureus and Staphylococcus epidermidis.
Borrero NV; Bai F; Perez C; Duong BQ; Rocca JR; Jin S; Huigens RW
Org Biomol Chem; 2014 Feb; 12(6):881-6. PubMed ID: 24389824
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.
Kim IH; Combrink KD; Ma Z; Chapo K; Yan D; Renick P; Morris TW; Pulse M; Simecka JW; Ding CZ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1181-4. PubMed ID: 17189695
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
Pyta K; Janas A; Szukowska M; Pecyna P; Jaworska M; Gajecka M; Bartl F; Przybylski P
Eur J Med Chem; 2019 Apr; 167():96-104. PubMed ID: 30769243
[TBL] [Abstract][Full Text] [Related]
13. Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via 'click chemistry' approach.
Pyta K; Klich K; Domagalska J; Przybylski P
Eur J Med Chem; 2014 Sep; 84():651-76. PubMed ID: 25063947
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.
Rothstein DM; Farquhar RS; Sirokman K; Sondergaard KL; Hazlett C; Doye AA; Gwathmey JK; Mullin S; van Duzer J; Murphy CK
Antimicrob Agents Chemother; 2006 Nov; 50(11):3658-64. PubMed ID: 16940074
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF
J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804
[TBL] [Abstract][Full Text] [Related]
16. Rifamycin O, An Alternative Anti-
Hanh BTB; Park JW; Kim TH; Kim JS; Yang CS; Jang K; Cui J; Oh DC; Jang J
Molecules; 2020 Mar; 25(7):. PubMed ID: 32244387
[No Abstract] [Full Text] [Related]
17. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS
Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Peek J; Koirala B; Brady SF
Bioorg Med Chem Lett; 2022 Feb; 57():128484. PubMed ID: 34861348
[TBL] [Abstract][Full Text] [Related]
19. Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.
Combrink KD; Ramos AR; Spring S; Schmidl S; Elizondo K; Morin P; De Jesus B; Maurer FP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2112-2115. PubMed ID: 31281018
[TBL] [Abstract][Full Text] [Related]
20. Isolation of 11,12- seco-Rifamycin W Derivatives Reveals a Cleavage Pattern of the Rifamycin Ansa Chain.
Shi Y; Zhang J; Tian X; Wu X; Li T; Lu C; Shen Y
Org Lett; 2019 Feb; 21(4):900-903. PubMed ID: 30714736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
